Magellan Rx Launches Value Plus, A Multi-State Medicaid VBC Solution For Cell & Gene Therapies

Magellan Rx Management (Magellan Rx), a Prime Therapeutics company, recently introduced Value Plus, a multi-state value-based contracting (VBC) solution focused on helping state Medicaid programs cover cell and gene therapies (CGT). The goal is to help state Medicaid programs secure access to CGT for Medicaid beneficiaries and to ensure that the cost of these therapies is linked to outcomes.

Unlike most traditional treatments, CGT are viewed as one-time therapies intended to cure or significantly alter the trajectory of a person’s disease. Cell therapies are typically priced close to $500,000 per treatment while gene therapies often . . .